In this webinar, our guest speakers will be discussing how to harness the full power of this disease-agnostic RNA platform, the key considerations needed for consistent, high-quality mRNA synthesis and how you can intensify manufacturing for rapid therapeutic production.

This inaugural event will showcase recent advances in the development of cell and gene therapies and the opportunities they provide for the treatment of disease and injury. Focus will be given to cancer immunotherapies and vaccines, stem cells, vector technologies and examples of genetic modification to treat a range of conditions.

In this webinar, our expert speakers will focus on various gene editing systems and how you can utilize analytical instrumentation to characterize the various components.

Outsourcing chemical supply to a trusted management partner offers significant benefits over self-managed alternatives. Benefits include greater flexibility, decreased risk, and higher raw material quality while the cost of ownership is reduced.

The polymerase chain reaction (qPCR) is firmly established as the method of choice for the detection of microbial agents in the areas of clinical, veterinary and agricultural diagnostics and food safety. The current pandemic has highlighted the critical importance of local, fast and specific testing for SARS-CoV-2. It should also act as a wake-up call for the threat posed by infectious diseases spreading because of climate change, increasing antibiotic resistance and the hazard of zoonotic transfer caused by human encroachment of animal habitats. We are working on new tests, protocol and reagents to achieve faster molecular diagnostic testing both for both laboratory based and POC applications. Our target of delivering a diagnostic test result within five minutes of sampling has the potential to lead to a paradigm shift in our approach to detecting and classifying microbial pathogens in preparation for the inevitable next pandemic

In this webinar, Professor Marius Wernig from Stanford University and Dr. Mark Kotter, CEO and founder of bit.bio offer an expert discussion on the pioneering research of cell reprogramming.